Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
Intervalo de ano de publicação
1.
Comput Struct Biotechnol J ; 20: 4473-4480, 2022.
Artigo em Inglês | MEDLINE | ID: mdl-36051870

RESUMO

Anticancer peptides are emerging anticancer drug that offers fewer side effects and is more effective than chemotherapy and targeted therapy. Predicting anticancer peptides from sequence information is one of the most challenging tasks in immunoinformatics. In the past ten years, machine learning-based approaches have been proposed for identifying ACP activity from peptide sequences. These methods include our previous method MLACP (developed in 2017) which made a significant impact on anticancer research. MLACP tool has been widely used by the research community, however, its robustness must be improved significantly for its continued practical application. In this study, the first large non-redundant training and independent datasets were constructed for ACP research. Using the training dataset, the study explored a wide range of feature encodings and developed their respective models using seven different conventional classifiers. Subsequently, a subset of encoding-based models was selected for each classifier based on their performance, whose predicted scores were concatenated and trained through a convolutional neural network (CNN), whose corresponding predictor is named MLACP 2.0. The evaluation of MLACP 2.0 with a very diverse independent dataset showed excellent performance and significantly outperformed the recent ACP prediction tools. Additionally, MLACP 2.0 exhibits superior performance during cross-validation and independent assessment when compared to CNN-based embedding models and conventional single models. Consequently, we anticipate that our proposed MLACP 2.0 will facilitate the design of hypothesis-driven experiments by making it easier to discover novel ACPs. The MLACP 2.0 is freely available at https://balalab-skku.org/mlacp2.

2.
Cell Mol Life Sci ; 75(13): 2303-2319, 2018 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-29602952

RESUMO

The Hippo tumor suppressor pathway, which is well conserved from Drosophila to humans, has emerged as the master regulator of organ size, as well as major cellular properties, such as cell proliferation, survival, stemness, and tissue homeostasis. The biological significance and deregulation of the Hippo pathway in tumorigenesis have received a surge of interest in the past decade. In the current review, we present the major discoveries that made substantial contributions to our understanding of the Hippo pathway and discuss how Hippo pathway components contribute to cellular signaling, physiology, and their potential implications in anticancer therapeutics.


Assuntos
Neoplasias/metabolismo , Proteínas Serina-Treonina Quinases/metabolismo , Transdução de Sinais/fisiologia , Animais , Proliferação de Células/fisiologia , Homeostase/fisiologia , Humanos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA